308 related articles for article (PubMed ID: 31277703)
1. Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model.
Rossaert E; Pollari E; Jaspers T; Van Helleputte L; Jarpe M; Van Damme P; De Bock K; Moisse M; Van Den Bosch L
Acta Neuropathol Commun; 2019 Jul; 7(1):107. PubMed ID: 31277703
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibition Regulates Lipid Homeostasis in a Mouse Model of Amyotrophic Lateral Sclerosis.
Burg T; Rossaert E; Moisse M; Van Damme P; Van Den Bosch L
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681883
[TBL] [Abstract][Full Text] [Related]
3. Trichostatin A Relieves Growth Suppression and Restores Histone Acetylation at Specific Sites in a FUS ALS/FTD Yeast Model.
Bennett SA; Cobos SN; Mirzakandova M; Fallah M; Son E; Angelakakis G; Rana N; Hugais M; Torrente MP
Biochemistry; 2021 Dec; 60(48):3671-3675. PubMed ID: 34788013
[TBL] [Abstract][Full Text] [Related]
4. Lysine acetylation regulates the RNA binding, subcellular localization and inclusion formation of FUS.
Arenas A; Chen J; Kuang L; Barnett KR; Kasarskis EJ; Gal J; Zhu H
Hum Mol Genet; 2020 Sep; 29(16):2684-2697. PubMed ID: 32691043
[TBL] [Abstract][Full Text] [Related]
5. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis.
Yoo YE; Ko CP
Exp Neurol; 2011 Sep; 231(1):147-59. PubMed ID: 21712032
[TBL] [Abstract][Full Text] [Related]
6. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
Ganai SA; Banday S; Farooq Z; Altaf M
Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic sequestration of FUS/TLS associated with ALS alters histone marks through loss of nuclear protein arginine methyltransferase 1.
Tibshirani M; Tradewell ML; Mattina KR; Minotti S; Yang W; Zhou H; Strong MJ; Hayward LJ; Durham HD
Hum Mol Genet; 2015 Feb; 24(3):773-86. PubMed ID: 25274782
[TBL] [Abstract][Full Text] [Related]
8. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
9. Effects of Class II-Selective Histone Deacetylase Inhibitor on Neuromuscular Function and Disease Progression in SOD1-ALS Mice.
Buonvicino D; Felici R; Ranieri G; Caramelli R; Lapucci A; Cavone L; Muzzi M; Di Pietro L; Bernardini C; Zwergel C; Valente S; Mai A; Chiarugi A
Neuroscience; 2018 May; 379():228-238. PubMed ID: 29588251
[TBL] [Abstract][Full Text] [Related]
10. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
11. Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models.
Kuta R; Larochelle N; Fernandez M; Pal A; Minotti S; Tibshirani M; St Louis K; Gentil BJ; Nalbantoglu JN; Hermann A; Durham HD
Cell Stress Chaperones; 2020 Jan; 25(1):173-191. PubMed ID: 31900865
[TBL] [Abstract][Full Text] [Related]
12. Low Level of Expression of C-Terminally Truncated Human FUS Causes Extensive Changes in the Spinal Cord Transcriptome of Asymptomatic Transgenic Mice.
Lysikova EA; Funikov S; Rezvykh AP; Chaprov KD; Kukharsky MS; Ustyugov A; Deykin AV; Flyamer IM; Boyle S; Bachurin SO; Ninkina N; Buchman VL
Neurochem Res; 2020 May; 45(5):1168-1179. PubMed ID: 32157564
[TBL] [Abstract][Full Text] [Related]
13. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients.
Guo W; Naujock M; Fumagalli L; Vandoorne T; Baatsen P; Boon R; Ordovás L; Patel A; Welters M; Vanwelden T; Geens N; Tricot T; Benoy V; Steyaert J; Lefebvre-Omar C; Boesmans W; Jarpe M; Sterneckert J; Wegner F; Petri S; Bohl D; Vanden Berghe P; Robberecht W; Van Damme P; Verfaillie C; Van Den Bosch L
Nat Commun; 2017 Oct; 8(1):861. PubMed ID: 29021520
[TBL] [Abstract][Full Text] [Related]
14. Beneficial and Sexually Dimorphic Response to Combined HDAC Inhibitor Valproate and AMPK/SIRT1 Pathway Activator Resveratrol in the Treatment of ALS Mice.
Bankole O; Scambi I; Parrella E; Muccilli M; Bonafede R; Turano E; Pizzi M; Mariotti R
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162978
[TBL] [Abstract][Full Text] [Related]
15. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.
Zhang L; Liu C; Wu J; Tao JJ; Sui XL; Yao ZG; Xu YF; Huang L; Zhu H; Sheng SL; Qin C
J Alzheimers Dis; 2014; 41(4):1193-205. PubMed ID: 24844691
[TBL] [Abstract][Full Text] [Related]
16. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
17. Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease.
Bennett SA; Tanaz R; Cobos SN; Torrente MP
Transl Res; 2019 Feb; 204():19-30. PubMed ID: 30391475
[TBL] [Abstract][Full Text] [Related]
18. ALS-causing mutations differentially affect PGC-1α expression and function in the brain vs. peripheral tissues.
Bayer H; Lang K; Buck E; Higelin J; Barteczko L; Pasquarelli N; Sprissler J; Lucas T; Holzmann K; Demestre M; Lindenberg KS; Danzer KM; Boeckers T; Ludolph AC; Dupuis L; Weydt P; Witting A
Neurobiol Dis; 2017 Jan; 97(Pt A):36-45. PubMed ID: 27818323
[TBL] [Abstract][Full Text] [Related]
19. FUS(1-359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy.
Funikov SY; Rezvykh AP; Mazin PV; Morozov AV; Maltsev AV; Chicheva MM; Vikhareva EA; Evgen'ev MB; Ustyugov AA
Neurogenetics; 2018 Aug; 19(3):189-204. PubMed ID: 29982879
[TBL] [Abstract][Full Text] [Related]
20. Effect of Class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice.
Lapucci A; Cavone L; Buonvicino D; Felici R; Gerace E; Zwergel C; Valente S; Mai A; Chiarugi A
Neurosci Lett; 2017 Aug; 656():120-125. PubMed ID: 28732762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
